SCHEMBL6475709

SCHEMBL6475709

CCN(CC)c1ccc(CCCc2ccc(Nc3ccc(C(=O)O)cc3OC)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 4/20 0.43
GAA P10253 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 1/20 0.43
MEN1 O00255 3/20 0.42
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 1/20 0.41
ESRRB O95718 1/20 0.41
ESRRG P62508 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
LTB4R Q15722 1/20 0.41
EGFR P00533 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CCR5 P51681 1/20 0.40
CA12 O43570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484606 0.83 RARB (0.50) MAPTALDH1A1KMT2AGAANPSR1
SCHEMBL6484538 0.81 MEN1 (0.58) MAPTALDH1A1HPGDKMT2AGAA
SCHEMBL6475576 0.79 MAPT (0.46) MAPTALDH1A1KMT2AGAANPSR1
SCHEMBL6482910 0.79 MEN1 (0.54) MAPTALDH1A1KMT2ANPSR1MEN1
SCHEMBL6474913 0.75 MEN1 (0.55) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL6528594 0.74 MEN1 (0.48) MAPTALDH1A1KMT2AGAANPSR1
SCHEMBL6474231 0.73 MAPT (0.56) MAPTALDH1A1KMT2AGAAMEN1
SCHEMBL21729816 0.73 CA12 (0.67) MAPTALDH1A1HPGDKMT2AHTT
SCHEMBL6481662 0.73 CTSV (0.58) MAPTALDH1A1KMT2AGAAHTT
SCHEMBL6474259 0.70 MEN1 (0.60) MAPTALDH1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MAPT 6/4885ALDH1A1 2945/4885HPGD 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.